Business Context and Reporting Period
This Form 8-K Current Report, filed on November 4, 2022, covers events occurring between November 4 and November 8, 2022, for NeuroBo Pharmaceuticals, Inc. (Note: The request metadata listed "Metavia Inc.", but the filing text explicitly identifies the registrant as NeuroBo Pharmaceuticals, Inc.). The report details the closing of a public offering and a concurrent private placement to Dong-A ST Co., Ltd. ("Dong-A"), alongside the licensing of assets from Dong-A.
Key Financial Metrics and Capital Structure
- Public Offering Proceeds: Net proceeds expected to be approximately $15.1 million after underwriting discounts and estimated offering expenses.
- Private Placement Proceeds: Gross proceeds of $15 million from Dong-A.
- License Upfront Payment: $22 million in Series A Convertible Preferred Stock issued to Dong-A as an upfront payment.
- Offering Price: $3.00 per Unit (Public Offering) and $3.00 per share conversion price for Preferred Stock.
- Securities Issued (Public Offering):
- 3,147,003 shares of Common Stock (including 750,000 from overallotment).
- 2,602,997 shares of Series B Convertible Preferred Stock.
- Warrants to purchase 11,500,000 shares of Common Stock.
- Securities Issued (Private Placement): Series A Convertible Preferred Stock and warrants to Dong-A.
- Outstanding Equity (as of Nov 8, 2022):
- 4,035,696 shares of Common Stock.
- 3,700 shares of Series A Convertible Preferred Stock (convertible into 12,333,333 shares of Common Stock).
- 2,602,997 shares of Series B Convertible Preferred Stock (convertible into 2,602,997 shares of Common Stock).
Note: The filing does not provide data on revenue, operating profit, cash flow, margins, or existing debt levels.
Material Changes and Transactions
The primary material change is the significant expansion of the company's capital base through the issuance of new equity and convertible securities. Key transactions include:
- Public Offering: Sold Class A Units (Common Stock + Warrants) and Class B Units (Series B Preferred Stock + Warrants). The 45-day overallotment option was exercised in full on November 7, 2022.
- Private Placement: Closed a private offering to Dong-A for $15 million in gross proceeds.
- Asset Licensing: Licensed assets from Dong-A, paying $22 million via the issuance of Series A Convertible Preferred Stock.
- Corporate Governance: Filed Certificates of Designation for Series A and Series B Convertible Preferred Stock with the Delaware Secretary of State.
Outlook, Risks, and Contingencies
- Stockholder Approval Requirement: The Series A Convertible Preferred Stock and the Warrants issued in both the public and private offerings are not convertible or exercisable until approved by the Company's stockholders.
- Lock-Up Period: The Company, its officers, directors, and certain stockholders are restricted from selling securities for 90 days following the closing or 30 days after stockholder approval of warrant exercisability, whichever is later.
- Beneficial Ownership Limitations: Holders cannot exercise warrants or convert preferred stock if it would result in beneficial ownership exceeding 4.99% (or 9.99% upon election) of outstanding Common Stock.
- Warrant Call Feature: The Company may call for cancellation of warrants if the stock price exceeds 300% of the exercise price ($3.00) for 20 consecutive trading days with sufficient volume.
- Unregistered Securities: Securities issued to Dong-A were offered under Section 4(a)(2) and Regulation D exemptions and are not registered under the Securities Act of 1933.
Investor Verification Checklist
- Verify the status of the pending stockholder vote required to make the Series A Preferred Stock and Warrants exercisable/convertible.
- Confirm the final net proceeds received after all offering expenses are settled.
- Review the specific terms of the License Agreement with Dong-A to understand the scope of licensed assets and future royalty obligations.
- Monitor the dilution impact of the 12,333,333 shares underlying the Series A Preferred Stock once conversion is permitted.
- Check for any subsequent filings regarding the exercise of the overallotment option (already noted as exercised in full) or changes in the warrant call conditions.